JP2018502579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502579A5 JP2018502579A5 JP2017536359A JP2017536359A JP2018502579A5 JP 2018502579 A5 JP2018502579 A5 JP 2018502579A5 JP 2017536359 A JP2017536359 A JP 2017536359A JP 2017536359 A JP2017536359 A JP 2017536359A JP 2018502579 A5 JP2018502579 A5 JP 2018502579A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically modified
- promoter
- medical
- cells
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 28
- 210000004027 cell Anatomy 0.000 claims 27
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- 208000019693 Lung disease Diseases 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 239000003623 enhancer Substances 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 1
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000007883 bronchodilation Effects 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007881 chronic fibrosis Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15150454.5 | 2015-01-08 | ||
| EP15150454 | 2015-01-08 | ||
| EP15191934.7 | 2015-10-28 | ||
| EP15191934 | 2015-10-28 | ||
| PCT/EP2016/050271 WO2016110565A1 (en) | 2015-01-08 | 2016-01-08 | Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199368A Division JP2021046416A (ja) | 2015-01-08 | 2020-12-01 | α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502579A JP2018502579A (ja) | 2018-02-01 |
| JP2018502579A5 true JP2018502579A5 (enExample) | 2019-02-14 |
Family
ID=55129837
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536359A Pending JP2018502579A (ja) | 2015-01-08 | 2016-01-08 | α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
| JP2020199368A Pending JP2021046416A (ja) | 2015-01-08 | 2020-12-01 | α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
| JP2022166094A Active JP7374527B2 (ja) | 2015-01-08 | 2022-10-17 | α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
| JP2023179480A Pending JP2024010006A (ja) | 2015-01-08 | 2023-10-18 | α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199368A Pending JP2021046416A (ja) | 2015-01-08 | 2020-12-01 | α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
| JP2022166094A Active JP7374527B2 (ja) | 2015-01-08 | 2022-10-17 | α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
| JP2023179480A Pending JP2024010006A (ja) | 2015-01-08 | 2023-10-18 | α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20180000969A1 (enExample) |
| EP (1) | EP3242933B1 (enExample) |
| JP (4) | JP2018502579A (enExample) |
| CN (1) | CN107208063A (enExample) |
| AU (1) | AU2016206033B2 (enExample) |
| CA (1) | CA2970993C (enExample) |
| CY (1) | CY1122004T1 (enExample) |
| DK (1) | DK3242933T3 (enExample) |
| ES (1) | ES2727820T3 (enExample) |
| HU (1) | HUE043478T2 (enExample) |
| IL (1) | IL253063B (enExample) |
| LT (1) | LT3242933T (enExample) |
| PL (1) | PL3242933T3 (enExample) |
| PT (1) | PT3242933T (enExample) |
| RS (1) | RS58977B1 (enExample) |
| SI (1) | SI3242933T1 (enExample) |
| SM (1) | SMT201900381T1 (enExample) |
| WO (1) | WO2016110565A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210086662A (ko) * | 2018-10-29 | 2021-07-08 | 오타와 하스피털 리서치 인스티튜트 | Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도 |
| CN109512893A (zh) * | 2018-11-05 | 2019-03-26 | 北京世纪劲得生物技术有限公司 | 间充质干细胞及其注射液和组合物在高尿酸血症中的应用 |
| JP7561348B2 (ja) * | 2019-07-31 | 2024-10-04 | 株式会社ステムリム | 間葉系幹細胞の増殖促進または減少抑制のための組成物 |
| EP4090349A4 (en) * | 2020-01-15 | 2024-06-05 | The Regents of The University of California | TRANSPLANTED CELL PROTECTION BY INHIBITING POLYMORPHENUCULAR CELLS |
| EP3964265A1 (en) * | 2020-09-07 | 2022-03-09 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof |
| EP4240323A1 (en) * | 2020-11-06 | 2023-09-13 | AATEC Medical GmbH | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
| WO2024005157A1 (ja) * | 2022-06-30 | 2024-01-04 | 国立大学法人熊本大学 | 脂肪細胞活性化剤 |
| CN116173218B (zh) * | 2023-04-28 | 2023-08-04 | 北京大学口腔医学院 | 蛋白转运抑制剂在制备用于治疗或缓解牙周炎的药物中的用途 |
| WO2025014986A2 (en) * | 2023-07-10 | 2025-01-16 | Precigen, Inc. | Therapy for alpha-1 antitrypsin deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266491A (en) * | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| WO2003089011A1 (en) | 2002-04-19 | 2003-10-30 | University Of Florida | rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES |
| US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| US9457070B2 (en) * | 2005-06-07 | 2016-10-04 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease |
| CA2697265A1 (en) | 2007-08-09 | 2009-02-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| WO2009046015A2 (en) | 2007-09-30 | 2009-04-09 | University Of Florida Research Foundation, Inc. | Combination therapies for treating type 1 diabetes |
| EP2626369A1 (en) * | 2011-11-24 | 2013-08-14 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Engineered mesenchymal stem cells and their therapeutic use |
| EP2793936A4 (en) * | 2011-12-19 | 2015-05-27 | Lfb Usa Inc | RECOMBINANT HUMAN ALPHA-1-ANTITRYPINE FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| CN102920735A (zh) | 2012-11-14 | 2013-02-13 | 青岛奥克生物开发有限公司 | 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用 |
| CN105456293A (zh) | 2014-09-05 | 2016-04-06 | 深圳市北科生物科技有限公司 | 一种用于治疗糖尿病的干细胞制剂及其制备方法 |
-
2016
- 2016-01-08 AU AU2016206033A patent/AU2016206033B2/en active Active
- 2016-01-08 CN CN201680005202.2A patent/CN107208063A/zh active Pending
- 2016-01-08 HU HUE16700404A patent/HUE043478T2/hu unknown
- 2016-01-08 WO PCT/EP2016/050271 patent/WO2016110565A1/en not_active Ceased
- 2016-01-08 LT LTEP16700404.3T patent/LT3242933T/lt unknown
- 2016-01-08 ES ES16700404T patent/ES2727820T3/es active Active
- 2016-01-08 PL PL16700404T patent/PL3242933T3/pl unknown
- 2016-01-08 RS RS20190634A patent/RS58977B1/sr unknown
- 2016-01-08 JP JP2017536359A patent/JP2018502579A/ja active Pending
- 2016-01-08 DK DK16700404.3T patent/DK3242933T3/da active
- 2016-01-08 PT PT16700404T patent/PT3242933T/pt unknown
- 2016-01-08 US US15/542,031 patent/US20180000969A1/en not_active Abandoned
- 2016-01-08 CA CA2970993A patent/CA2970993C/en active Active
- 2016-01-08 SM SM20190381T patent/SMT201900381T1/it unknown
- 2016-01-08 SI SI201630262T patent/SI3242933T1/sl unknown
- 2016-01-08 EP EP16700404.3A patent/EP3242933B1/en active Active
-
2017
- 2017-06-21 IL IL253063A patent/IL253063B/en active IP Right Grant
-
2019
- 2019-05-24 CY CY20191100553T patent/CY1122004T1/el unknown
-
2020
- 2020-02-25 US US16/800,840 patent/US20200282078A1/en not_active Abandoned
- 2020-12-01 JP JP2020199368A patent/JP2021046416A/ja active Pending
-
2022
- 2022-10-17 JP JP2022166094A patent/JP7374527B2/ja active Active
-
2023
- 2023-03-31 US US18/194,383 patent/US20230226222A1/en active Pending
- 2023-10-18 JP JP2023179480A patent/JP2024010006A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502579A5 (enExample) | ||
| JP2024010006A5 (enExample) | ||
| Dubey et al. | Oral peptide delivery: Challenges and the way ahead | |
| JP2015517489A5 (enExample) | ||
| US20080167230A1 (en) | Methods and compositions for treating or preventing lesions of the respiratory epithelium | |
| Gulati et al. | Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects | |
| Nainwal et al. | Dry powder inhalers of antitubercular drugs | |
| JP2010508365A5 (enExample) | ||
| Williams et al. | Advances in treating bronchopulmonary dysplasia | |
| Gulati et al. | Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases | |
| RU2010113994A (ru) | Применение панкреатического полипептида человека в качестве терапевтического средства | |
| Fantacci et al. | Pneumopericardium, pneumomediastinum, and pneumorrachis complicating acute respiratory syncytial virus bronchiolitis in children | |
| Lin et al. | Combined intravenous ribavirin and recombinant human interferon α1b aerosol inhalation for adenovirus pneumonia with plastic bronchitis in children: a case report and review of literature | |
| US6592848B1 (en) | Mixtures of oxygen and helium for the treatment of respiratory insufficiency | |
| JP2016510040A5 (enExample) | ||
| Nojima et al. | Plastic bronchitis in a five-year-old boy treated using extracorporeal membrane oxygenation; a case report | |
| RU2010114008A (ru) | ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ГАСТРИНА 1 И G-Pen-GRGDSPCA | |
| HRP20190921T1 (hr) | Genetski modificirane mezenhimske matične stanice koje ekprimiraju alfa-1 antitripsin (aat) | |
| JP2013528622A5 (enExample) | ||
| EP1941883A1 (en) | Use of sodium blockers for an early therapy of obstructive lung diseases | |
| Averyanov et al. | Inhaled surfactant in patients with covid-19 who took high-flow oxygen: The results of a retrospective analysis | |
| Abbasi et al. | Extracorporeal life support in adults with acute respiratory failure: current evidence-based practices | |
| Shaikh et al. | Recent trends in applications of pulmonary drug delivery: a review | |
| FI3723790T3 (fi) | Menetelmiä immuunitoleranssin indusoimiseksi ja lääkevasta-ainevasteen vähentämiseksi | |
| Nizam et al. | Takotsubo Syndrome After Liver Transplantation. |